Premium
PilVax, a novel Lactococcus lactis ‐based mucosal vaccine platform, stimulates systemic and mucosal immune responses to Staphylococcus aureus
Author(s) -
Clow Fiona,
Peterken Kelly,
Pearson Victoria,
Proft Thomas,
Radcliff Fiona J
Publication year - 2020
Publication title -
immunology and cell biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.999
H-Index - 104
eISSN - 1440-1711
pISSN - 0818-9641
DOI - 10.1111/imcb.12325
Subject(s) - staphylococcus aureus , nasal administration , microbiology and biotechnology , lactococcus lactis , immune system , antigen , immunology , antibody , intestinal mucosa , immunoglobulin a , mucous membrane of nose , biology , epitope , immunoglobulin g , virology , medicine , bacteria , lactic acid , genetics
Most pathogens initiate infection via the mucosa, therefore delivery of vaccines directly to the mucosa is likely to be advantageous for stimulating protective immunity at the site of entry. PilVax is a novel mucosal vaccine platform that harnesses Lactococcus lactis bacteria engineered to stably express multiple copies of vaccine peptide antigens within pili, hair‐like structures which extend from the cell wall. This strategy elicited systemic and mucosal antibody responses to a model antigen after intranasal immunization, but has not been tested for its capacity to stimulate protective mucosal immunity. A well‐characterized linear B‐cell epitope, D3 (22–33) , from the fibronectin‐binding protein A of Staphylococcus aureus was successfully introduced into PilVax and delivered intranasally to mice. Specific antipeptide immunoglobulin (Ig) G and IgA antibodies were detected in the serum and respiratory mucosa of vaccinated mice. Responses to the major pilus backbone protein Spy0128 were also assessed; robust antibody responses to this antigen were generated both systemically and in the respiratory and intestinal mucosa. Mice were challenged intranasally with the mouse‐adapted S. aureus JSNZ strain and the S. aureus load quantified 7 days after challenge. Unexpectedly, exposure to PilVax, irrespective of the presence of the peptide, resulted in a significant reduction in S. aureus load in both the intestine and nasal mucosa (both P < 0.05) when compared with unvaccinated control mice. The mechanism(s) of protection are unclear, but merit further investigation to determine whether PilVax is a suitable platform for delivery of vaccine candidate antigens to the mucosa.